-

02:25:23 AM

IDYA Stock News

IDYA - Ideaya Biosciences Inc

02/01/23 6:00 AM

Nasdaq : IDYA

conferences

IDEAYA Biosciences to Participate in the 2023 Guggenheim Oncology Conference

IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the 2023 Guggenheim Oncology Conference. 2023 Guggenheim Oncology Conference Thursday, February 9, 2023 at 7:45 AM PT. Fireside chat with Yujiro S. Hata,...

RHEA-AI

neutral

01/23/23 6:00 AM

Nasdaq : IDYA

clinical trial

IDEAYA Announces Darovasertib Phase 2 Initiation in Neoadjuvant and Adjuvant Uveal Melanoma and Guidance for Clinical Data Update in Metastatic Uveal Melanoma

- Initiated Phase 2 clinical trial evaluating Darovasertib as neoadjuvant treatment of uveal melanoma prior to primary interventional treatment of enucleation or radiation therapy- Clinical protocol includes neoadjuvant treatment with Darovasertib to maximum benefit up to 6 months, primary

RHEA-AI

neutral

01/09/23 6:00 AM

Nasdaq : IDYA

clinical trial

IDEAYA Announces IND Clearance by U.S. FDA enabling Phase 1 Initiation for First-in-Class PARG Development Candidate IDE161

- Targeting to initiate dosing of Phase 1 clinical trial in Q1 2023 to evaluate IDE161 in patients having tumors with HRD, including BRCA1/2-mutant breast and ovarian cancer- Starting dose of IDE161 in the Phase 1 dose escalation is one-half of the projected human efficacious dose, based on

RHEA-AI

neutral

01/03/23 6:00 AM

Nasdaq : IDYA

conferences

IDEAYA Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation at the 41st Annual J.P. Morgan

RHEA-AI

neutral

12/19/22 6:00 AM

Nasdaq : IDYA

management

IDEAYA Biosciences Appoints Dr. Karlene Cimprich, Ph.D. and Dr. Kornelia Polyak, M.D., Ph.D. to Scientific Advisory Board

- Dr. Karlene Cimprich, Ph.D. ( Stanford University), is a leading scientist in replication stress mechanisms and regulation of DNA Damage Repair pathways- Dr. Kornelia Polyak, M.D., Ph.D. (DFCI, Harvard University) is a renowned physician-scientist focused on breast cancer clinical

RHEA-AI

neutral

12/12/22 6:00 AM

Nasdaq : IDYA

IDEAYA Biosciences Announces Submission of IND Application to the U.S. FDA for PARG Development Candidate IDE161

- IDE161 is being developed as a potential first-in-class PARG inhibitor for patients having tumors with HRD, with an initial focus in BRCA1/2-mutant Breast and Ovarian Cancer- Proposed clinical development plan for IDE161 to be highlighted in Investor R&D Day webcast being hosted by IDEAYA

RHEA-AI

neutral

12/05/22 6:00 AM

Nasdaq : IDYA

IDEAYA Biosciences Receives Fast Track Designation for Darovasertib Combination Therapy with Crizotinib for the Treatment of Metastatic Uveal Melanoma

Fast Track designation granted by U.S. FDA for evaluation of darovasertib in combination with crizotinib in adult patients being treated for metastatic uveal melanoma (MUM) Enables darovasertib / crizotinib development program to access expedited regulatory review processes, including potential

RHEA-AI

very positive

11/29/22 6:00 AM

Nasdaq : IDYA

IDEAYA Biosciences Announces Agenda Topics and Key Opinion Leader Presenters for Investor R&D Day Webcast on Monday, December 12, 2022

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced agenda topics and participating key opinion leaders

RHEA-AI

neutral

11/28/22 6:00 AM

Nasdaq : IDYA

managementclinical trial

IDEAYA Biosciences Appoints Darrin M. Beaupre, M.D., Ph.D., as Chief Medical Officer to Lead Clinical Development of Expanding Clinical Pipeline

Former Senior Vice President and Head of Early Oncology Development and Clinical Research at Pfizer will lead IDEAYA's clinical development efforts as Chief Medical Officer Over twenty-five years of experience in clinical development and translational research, including at leading pharmaceutical

RHEA-AI

neutral

11/08/22 6:00 AM

Nasdaq : IDYA

earnings

IDEAYA Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update

Strong balance sheet of $393.9 million cash, cash equivalents and marketable securities as of September 30, 2022 is anticipated to fund planned operations into 2026 Reported Phase 2 interim clinical data for darovasertib and crizotinib combination in MUM; subject to FDA guidance, targeting

RHEA-AI

positive

1 2 3 4 5 6 7 8 9 Next

IDYA Data

IndustryResearch and Development in Biotechnology
Websitewww.ideayabio.com
CeoYujiro Hata
Security nameIdeaya Biosciences Inc
Issue typecs
SectorProfessional, Scientific, and Technical Services
Sic code2834
Employees62
Tags
- Biotechnology
- Pharmaceuticals: Major
- Health Technology
Address7000 Shoreline Ct Ste 350
StateCalifornia
CitySouth San Francisco
Zip94080-7604
CountryUS
Phone16504436209

About Ideaya Biosciences Inc

IDEAYA Biosciences Inc. is a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality - which represents an emerging class of precision medicine targets.